Epidemiology

You have full text access to this OnlineOpen article

HMG-CoA reductase expression in breast cancer is associated with a less aggressive phenotype and influenced by anthropometric factors

  1. Signe Borgquist1,2,
  2. Soraya Djerbi3,
  3. Fredrik Pontén4,
  4. Lola Anagnostaki1,
  5. Malin Goldman1,
  6. Alexander Gaber1,
  7. Jonas Manjer5,6,
  8. Göran Landberg1,
  9. Karin Jirström1,†,*

Article first published online: 4 JUN 2008

DOI: 10.1002/ijc.23597

Issue

International Journal of Cancer

International Journal of Cancer

Volume 123, Issue 5, pages 1146–1153, 1 September 2008

Additional Information

How to Cite

Borgquist, S., Djerbi, S., Pontén, F., Anagnostaki, L., Goldman, M., Gaber, A., Manjer, J., Landberg, G. and Jirström, K. (2008), HMG-CoA reductase expression in breast cancer is associated with a less aggressive phenotype and influenced by anthropometric factors. Int. J. Cancer, 123: 1146–1153. doi: 10.1002/ijc.23597

Author Information

  1. 1

    Department of Laboratory Medicine, Center for Molecular Pathology, Malmö University Hospital, Malmö, Sweden

  2. 2

    Department of Clinical Sciences, Division of Oncology, Lund University Hospital, Lund, Sweden

  3. 3

    Atlas Antibodies AB, AlbaNova University Center, Stockholm, Sweden

  4. 4

    Rudbeck Laboratory, Department of Genetics and Pathology, Uppsala University, Uppsala, Sweden

  5. 5

    Department of Surgery, Malmö University Hospital; Malmö, Sweden

  6. 6

    The Malmö Diet and Cancer Study, Malmö University Hospital, Malmö, Sweden

  1. †

    Fax: +46-40-337063.

*Center for Molecular Pathology, Department of Laboratory Medicine, Lund University, Malmö University Hospital, SE-205 02 Malmö, Sweden

Publication History

  1. Issue published online: 17 JUN 2008
  2. Article first published online: 4 JUN 2008
  3. Manuscript Accepted: 4 MAR 2008
  4. Manuscript Received: 12 DEC 2007

Funded by

  • Swedish Cancer Society
  • Swegene/Wallenberg Consortium North
  • Malmö University Hospital Research Funds

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (287K)

References

  • 1
    Mo H,Elson CE. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med (Maywood). 2004; 229: 567–85.
  • 2
    Goldstein JL,Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425–30.
  • 3
    Shachaf CM,Perez OD,Youssef S,Fan AC,Elchuri S,Goldstein MJ,Shirer AE,Sharpe O,Chen J,Mitchell DJ,Chang M,Nolan GP, et al. Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. Blood 2007; 110: 2674–84.
  • 4
    Di Croce L,Bruscalupi G,Trentalance A. Independent behavior of rat liver LDL receptor and HMGCoA reductase under estrogen treatment. Biochem Biophys Res Commun 1996; 224: 345–50.
  • 5
    Ma PT,Yamamoto T,Goldstein JL,Brown MS. Increased mRNA for low density lipoprotein receptor in livers of rabbits treated with 17 alpha-ethinyl estradiol. Proc Natl Acad Sci USA 1986; 83: 792–6.
  • 6
    Di Croce L,Vicent GP,Pecci A,Bruscalupi G,Trentalance A,Beato M. The promoter of the rat 3-hydroxy-3-methylglutaryl coenzyme A reductase gene contains a tissue-specific estrogen-responsive region. Mol Endocrinol 1999; 13: 1225–36.
  • 7
    Messa C,Notarnicola M,Russo F,Cavallini A,Pallottini V,Trentalance A,Bifulco M,Laezza C,Gabriella Caruso M. Estrogenic regulation of cholesterol biosynthesis and cell growth in DLD-1 human colon cancer cells. Scand J Gastroenterol 2005; 40: 1454–61.
  • 8
    Lennernas H,Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet 1997; 32: 403–25.
  • 9
    Sivaprasad U,Abbas T,Dutta A. Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells. Mol Cancer Ther 2006; 5: 2310–6.
  • 10
    Campbell J,Esserman LJ,Zhou Y,Shoemaker M,Lobo M,Borman E,Baehner F,Kumar AS,Adduci K,Marx C,Petricoin EF,Liotta LA, et al. Breast cancer growth prevention by statins. Cancer Res 2006; 66: 8707–14.
  • 11
    Duncan RE,Lau D,El-Sohemy A,Archer MC. Geraniol and beta-ionone inhibit proliferation, cell cycle progression, and cyclin-dependent kinase 2 activity in MCF-7 breast cancer cells independent of effects on HMG-CoA reductase activity. Biochem Pharmacol 2004; 68: 1739–47.
  • 12
    Graaf MR,Beiderbeck AB,Egberts AC,Richel DJ,Guchelaar HJ. The risk of cancer in users of statins. J Clin Oncol 2004; 22: 2388–94.
  • 13
    Strandberg TE,Pyorala K,Cook TJ,Wilhelmsen L,Faergeman O,Thorgeirsson G,Pedersen TR,Kjekshus J. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004; 364: 771–7.
  • 14
    Poynter JN,Gruber SB,Higgins PD,Almog R,Bonner JD,Rennert HS,Low M,Greenson JK,Rennert G. Statins and the risk of colorectal cancer. N Engl J Med 2005; 352: 2184–92.
  • 15
    Boudreau DM,Yu O,Miglioretti DL,Buist DS,Heckbert SR,Daling JR. Statin use and breast cancer risk in a large population-based setting. Cancer Epidemiol Biomarkers Prev 2007; 16: 416–21.
  • 16
    Bonovas S,Filioussi K,Tsavaris N,Sitaras NM. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 2005; 23: 8606–12.
  • 17
    Berglund G,Elmstahl S,Janzon L,Larsson SA. The Malmo Diet and Cancer Study. Design and feasibility. J Intern Med 1993; 233: 45–51.
    Direct Link:
  • 18
    Yasui T,Uemura H,Umino Y,Takikawa M,Saito S,Kuwahara A,Matsuzaki T,Maegawa M,Furumoto H,Miura M,Irahara M. Serum estrogen level after hormone replacement therapy and body mass index in postmenopausal and bilaterally ovariectomized women. Maturitas 2005; 50: 19–29.
  • 19
    [Histological typing of breast tumors. Second edn. World Health Organization. Geneva, 1981]. Ann Pathol 1982; 2: 91–105.
  • 20
    Elston CW,Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403–10.
    Direct Link:
  • 21
    Borgquist S,Anagnostaki L,Jirstrom K,Landberg G,Manjer J. Breast tumours following combined hormone replacement therapy express favourable prognostic factors. Int J Cancer 2007; 120: 2202–7.
    Direct Link:
  • 22
    Dowsett M,Bartlett J,Ellis IO,Salter J,Hills M,Mallon E,Watters AD,Cooke T,Paish C,Wencyk PM,Pinder SE. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 2003; 199: 418–23.
    Direct Link:
  • 23
    Huang Z,Willett WC,Colditz GA,Hunter DJ,Manson JE,Rosner B,Speizer FE,Hankinson SE. Waist circumference, waist:hip ratio, and risk of breast cancer in the Nurses' Health Study. Am J Epidemiol 1999; 150: 1316–24.
  • 24
    Feigelson HS,Jonas CR,Teras LR,Thun MJ,Calle EE. Weight gain, body mass index, hormone replacement therapy, and postmenopausal breast cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev 2004; 13: 220–4.
  • 25
    Morimoto LM,White E,Chen Z,Chlebowski RT,Hays J,Kuller L,Lopez AM,Manson J,Margolis KL,Muti PC,Stefanick ML,McTiernan A. Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control 2002; 13: 741–51.
  • 26
    Celis JE,Gromova I,Gromov P,Moreira JM,Cabezon T,Friis E,Rank F. Molecular pathology of breast apocrine carcinomas: a protein expression signature specific for benign apocrine metaplasia. FEBS Lett 2006; 580: 2935–44.
  • 27
    Sever N,Yang T,Brown MS,Goldstein JL,DeBose-Boyd RA. Accelerated degradation of HMG CoA reductase mediated by binding of insig-1 to its sterol-sensing domain. Mol Cell 2003; 11: 25–33.
  • 28
    Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419–27.
  • 29
    Aboushadi N,Shackelford JE,Jessani N,Gentile A,Krisans SK. Characterization of peroxisomal 3-hydroxy-3-methylglutaryl coenzyme A reductase in UT2 cells: sterol biosynthesis, phosphorylation, degradation, and statin inhibition. Biochemistry 2000; 39: 237–47.
View Full Article (HTML) Get PDF (287K)